Egrifta (Tesamorelin) + MOTS-c: When to Pick One Over the Stack

Why this comparison is not close

Tesamorelin has been given to 740 HIV-infected patients with lipodystrophy and excess abdominal fat in clinical trials, 543 of them during the 26-week placebo-controlled phase [2]. When FDA reviewed MOTS-c in July 2026, the 12 papers the nominator cited were not clinical studies [1].

So the real choice is not between two comparable drugs. It is between an approved prescription product with trial data, label warnings and monitoring requirements, and an unapproved peptide for which FDA found no human data [1][2].

What tesamorelin does and who it is approved for

Egrifta (tesamorelin acetate) was approved on November 10, 2010, as BLA 022505 [7]. The current labels are Egrifta SV, a 2 mg vial given as 1.4 mg once daily, and Egrifta WR, an 11.6 mg vial given as 1.28 mg once daily; both are subcutaneous injections into the abdomen, and the labels state the two are not substitutable [2][3].

Tesamorelin is a synthetic analog of human growth hormone-releasing factor: the 44-amino-acid human sequence with a hexenoyl group on the N-terminal tyrosine, molecular weight about 5135.9 Da [2]. It binds pituitary GRF receptors and stimulates release of the body's own growth hormone, which raises IGF-1 and IGFBP-3 [2].

The indication is narrow. The label covers reduction of excess abdominal fat in HIV-infected adults with lipodystrophy, and adds that long-term cardiovascular safety has not been established, that it is not indicated for weight loss management because its effect on weight is neutral, and that there are no data showing it improves adherence to antiretroviral therapy [2]. Use in anyone without HIV lipodystrophy sits outside that label.

The trial numbers

Study 1 (Falutz 2007, NEJM) randomized 412 HIV-infected adults with excess abdominal fat to tesamorelin 2 mg daily or placebo for 26 weeks. Visceral adipose tissue fell 15.2% on tesamorelin and rose 5.0% on placebo; triglycerides fell 50 mg/dL versus a rise of 9 mg/dL; IGF-1 rose 81.0% versus a fall of 5.0% (P<0.001 for all comparisons) [4]. Study 2 (Falutz 2010, JAIDS) randomized 404 patients in a 2:1 ratio and found visceral fat down 10.9% versus 0.6% at 6 months [8]. A pooled analysis of the two trials, 806 patients in all (543 tesamorelin, 263 placebo), reported visceral fat changes of -24 cm2 versus +2 cm2, a treatment effect of -15.4% [9].

The effect is not permanent. In the extension phases, patients switched to placebo from week 26 to week 52 gained visceral fat back (+16% to +22%), while those who continued changed by 0% to -5% [2].

A separate 50-patient trial (Stanley 2014, JAMA) found visceral fat -34 cm2 versus +8 cm2 with placebo over 6 months, and liver fat down a median 2.0 percentage points versus up 0.9 [10].

What MOTS-c is and what is actually known

MOTS-c is a 16-amino-acid peptide encoded in mitochondrial DNA, first reported in 2015 [1][11]. In mice, the original Cell Metabolism paper reported that MOTS-c treatment prevented age-dependent and high-fat-diet-induced insulin resistance and diet-induced obesity, with skeletal muscle as the main target and AMPK activation downstream of inhibited folate-cycle metabolism [11]. A 2021 Nature Communications study found that MOTS-c injection improved physical performance in young, middle-aged and old mice, and that late-life intermittent treatment increased physical capacity and healthspan; in humans that study measured only that exercise raises the body's own MOTS-c in muscle and in circulation [12].

The human exercise data are modest. In a randomized trial of 30 healthy adults (10 endurance, 10 resistance, 10 control), circulating humanin rose after endurance exercise while MOTS-c showed only a trend to increase, and plasma levels were not related to fitness [13]. Nobody in that trial was given MOTS-c.

FDA also found no pharmacokinetic data for MOTS-c in humans or in live animals; the one kinetic observation is that it breaks down quickly in human blood in vitro, which raises the question whether injecting it can produce active levels in people [1]. No human dose has been established: the uses nominated to FDA were 5 mg and 10 mg subcutaneous injections, and the mouse doses of 0.5 to 15 mg/kg cannot be converted into a human dose [1]. Safety is unmeasured rather than established. FDA found no animal toxicity studies, its adverse-event database search through March 9, 2025 returned no MOTS-c reports, and its stated concern for injectable peptides is immunogenicity from aggregation and peptide-related impurities [1].

Is there a real case for the stack?

Tesamorelin stimulates growth hormone release [2]. The MOTS-c findings on muscle metabolism and AMPK activation come from laboratory and mouse studies [11]. Those findings do not establish how the two would work together in people.

Because FDA found no study in which MOTS-c was given to a person, there is no human dose, interaction profile or safety record for MOTS-c alone, let alone for a combination with tesamorelin [1].

When tesamorelin is the one to pick

The clearest case for tesamorelin alone is the labeled one: an HIV-infected adult with lipodystrophy and excess abdominal fat, which is the population the two pivotal trials enrolled [2][4].

The label also defines who it is not for. Tesamorelin is contraindicated in people with disruption of the hypothalamic-pituitary axis (hypophysectomy, hypopituitarism, pituitary tumor or surgery, head irradiation or head trauma), active malignancy, known hypersensitivity to tesamorelin or its excipients, and pregnancy; any preexisting malignancy should be inactive and its treatment complete before starting [2].

The label flags two interaction areas. Growth hormone inhibits 11-beta-HSD1, the enzyme that converts cortisone to active cortisol, so patients receiving glucocorticoid replacement for hypoadrenalism may need higher maintenance or stress doses after starting, with cortisone acetate and prednisone affected more than other steroids [2]. Published data also suggest growth hormone can alter clearance of drugs metabolized by CYP450 enzymes (corticosteroids, sex steroids, anticonvulsants, cyclosporine), and the label says to monitor for interactions [2].

What choosing MOTS-c instead actually involves

MOTS-c is not an FDA-approved drug and is not a component of one; FDA's July 2026 review found no USP or National Formulary monograph, no listing in the European or Japanese pharmacopeias, and no product authorized by the European Medicines Agency [1].

Its regulatory position is unfinished, not settled. FDA staff proposed in a July 2026 briefing document that neither MOTS-c free base nor acetate be added to the compounding bulks list, citing poor characterization and the lack of human safety, effectiveness and animal toxicity data [1]. The Pharmacy Compounding Advisory Committee voted the other way on July 23, 2026, but that is advice only and not binding, and MOTS-c is not on the list [14][15]. HHS's draft enforcement-discretion policy, filed October 28, 2026, names MOTS-c among six peptides and says HHS does not intend to take enforcement action against certain state-licensed pharmacies and physicians compounding MOTS-c acetate for injection if conditions are met; the notice states it is not binding, establishes no rights, and is not an approval [15][16]. Compounded drugs are not FDA-approved, and FDA does not review their safety, effectiveness or quality before marketing [15].

Tesamorelin sits differently: it does not appear on FDA's list of bulk substances that may present significant safety risks, and appears in no category of FDA's lists for state-licensed pharmacies and outsourcing facilities, so FDA has made no category-based statement about compounding it [17][18][19]. It is also not one of the six peptides in the HHS draft policy [15][16].

For anyone subject to anti-doping rules, both are prohibited at all times, in and out of competition: WADA names tesamorelin in S2.2.4 as a growth hormone releasing factor and MOTS-c in S4.4.1 as an AMPK activator, on the 2026 List and the 2027 List [5][6].

What the Egrifta label asks prescribers to monitor

IGF-1: the label says to monitor IGF-1 and consider discontinuing with persistent elevations such as above 3 SDS, particularly if the fat-loss response is not robust. Among patients treated 26 weeks, 47% had IGF-1 above 2 SDS and 36% above 3 SDS, seen as early as 13 weeks; among those treated 52 weeks, 34% and 23% [2]. The effects of prolonged IGF-1 elevation are unknown [2].

Glucose: the label says tesamorelin can cause glucose intolerance or diabetes, and asks prescribers to evaluate glucose before and during therapy. HbA1c of 6.5% or higher developed in 5% of tesamorelin patients versus 1% on placebo by week 26, a hazard ratio of 3.3 (95% CI 1.4 to 9.6); the label says patients with diabetes should be monitored at regular intervals for retinopathy [2].

Other labeled reactions include fluid retention (edema, joint pain, carpal tunnel syndrome), hypersensitivity in 4% of trial patients (itching, redness, flushing, hives, rash; the label advises prompt medical attention and discontinuation if suspected), and injection-site reactions in 25% versus 14% on placebo over the first 26 weeks [2]. The most common reactions, above 5%, were arthralgia, injection-site redness, injection-site itching, extremity pain, peripheral edema and myalgia [2]. Neither current label carries a boxed warning [2][3].